Literature DB >> 1991908

Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations.

B D Robalino1, D S Moodie.   

Abstract

To determine the clinical, laboratory and hemodynamic profile in patients with primary pulmonary hypertension and associated portal hypertension, 7 new cases and 71 previously reported cases were analyzed. There was no gender predilection and the average age at diagnosis was 41 years. Liver cirrhosis was the most frequent cause of hypertension (82%) and a surgical portosystemic shunt was present in 29%. Almost invariably, portal hypertension either preceded or was diagnosed concurrently with pulmonary hypertension, favoring the hypothesis that in portal hypertension, the pulmonary vasculature may be exposed to vasoactive substances normally metabolized or produced by the diseased liver, possibly inducing vasoconstriction or direct toxic damage to the pulmonary arteries. Clinically, exertional dyspnea was the most frequent presenting symptom (81%); other symptoms, such as syncope, chest pain and fatigue, were present in less than 33%. An accentuated pulmonary component of the second heart sound (82%) and a systolic murmur (69%) were the most common physical findings. At least 75% of these patients had evidence of pulmonary hypertension on electrocardiography (right ventricular hypertrophy) or roentgenography (cardiomegaly or dilated main pulmonary arteries, or both). Hemodynamic findings included severe pulmonary hypertension (mean pulmonary artery pressure 59 +/- 19 mm Hg) with normal pulmonary capillary wedge pressure and cardiac output. Treatment was basically palliative and the mean and median survival times were 15 and 6 months, respectively. In brief, on the basis of clinical presentation and laboratory features, patients with combined primary pulmonary hypertension and portal hypertension seldom represent a diagnostic challenge. Further research is needed on treatment, which remains palliative. The survival rate is poor and worse than that seen in isolated primary pulmonary hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1991908     DOI: 10.1016/s0735-1097(10)80121-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  44 in total

Review 1.  Primary pulmonary hypertension.

Authors:  A J Peacock
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

2.  Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth.

Authors:  C D Cool; J S Stewart; P Werahera; G J Miller; R L Williams; N F Voelkel; R M Tuder
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

3.  Hepatopulmonary syndromes.

Authors:  M J Krowka
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

4.  Esophageal variceal ligation for esophageal variceal hemorrhage in a patient with portal and primary pulmonary hypertension complicating myelofibrosis.

Authors:  W C Lee; H C Lin; S H Tsay; Y Y Yang; M C Hou; F Y Lee; F Y Chang; S D Lee
Journal:  Dig Dis Sci       Date:  2001-04       Impact factor: 3.199

5.  Portopulmonary hypertension: challenges in diagnosis and management.

Authors:  Patrick J Troy; Aaron B Waxman
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

Review 6.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

Review 7.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; John C Marecki; Amy Richter; Iwona Fijalkowska; Sonia Flores
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

Review 8.  Hepato-cardiac disorders.

Authors:  Yasser Mahrous Fouad; Reem Yehia
Journal:  World J Hepatol       Date:  2014-01-27

9.  Serotonin transporter polymorphisms in patients with portopulmonary hypertension.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Raymond L Benza; James A Knowles; David B Badesch; Robert S Brown; Darren B Taichman; James Trotter; Steven Zacks; Evelyn M Horn; Steven M Kawut
Journal:  Chest       Date:  2009-01-13       Impact factor: 9.410

10.  Pulmonary hypertension associated with primary biliary cirrhosis in the absence of portal hypertension: a case report.

Authors:  E M Yoshida; S R Erb; D N Ostrow; D R Ricci; C H Scudamore; G Fradet
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.